Podcasts about Menin

Julie Menin, the presumptive next Speaker of the New York City Council, joined host Ben Max and Andrew Rein, president of Citizens Budget Commission, for a conversation at New York Law School on her path to the speakership, her priorities when she takes the position in January, how she plans to work with Mayor Zohran Mamdani, and more. The event took place on December 10, 2025 and was hosted by NYLS' Center for New York City and State Law and Citizens Budget Commission. Menin declared victory in the speaker race in late November, and will have to be officially voted into the position by her Council colleagues in early January. (Ep 553)

Following right-wing Democrat Julie Menin's victory in the race for City Council Speaker, we spoke with Brandon West, a former member of the City Council's central staff, about how Menin and her supporters outmaneuvered progressives, the powers she will wield as speaker and how she might try to obstruct Zohran Mamdani when he is mayor.

Eksik Olan'ın bu bölümünde Ömer Çeşit ile Alp Kozanoğlu, Mike Davis'in kült eseri “Gecekondu Gezegeni” üzerinden şehirleşmenin karanlık yüzünü tartışıyor. 2003'te yayımlanan kitap, hızla büyüyen gecekondu yerleşkelerini ve neoliberal düzenin yarattığı yapısal eşitsizlikleri mercek altına alıyor. Mega-gecekondu kentlerinin kendi iç dinamikleri, kültürel etkileri ve ekolojik sonuçları konuşuluyor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Featuring an interview with Dr Ghayas Issa, including the following topics: Mechanism of action and efficacy of menin inhibitors (0:00) Presentation and management of differentiation syndrome (13:31) Role of menin inhibitors in other cancers (18:19) Case: A woman in her mid 40s with KMT2A-rearranged acute myeloid leukemia (AML) after treatment for breast cancer (20:51) Mechanisms of resistance to menin inhibition in AML (26:53) Case: A woman in her early 70s with monocytic AML and multiple mutations including NPM1 experienced complete response with ziftomenib (32:31) Mechanism of action of menin inhibitors as differentiation agents (38:05) Similarities and differences between approved and investigational menin inhibitors under clinical development for the treatment of AML (45:55) Dual targeted therapy and other novel treatment approaches under clinical evaluation with menin inhibitors (51:25) Other investigational therapeutic strategies in AML (54:39) CME information and select publications

Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Ghayas Issa, including the following topics: Evolution of menin inhibitors for acute myeloid leukemia (AML) (0:00) Side effects of menin inhibition (10:54) Mechanisms of resistance to menin inhibition in AML (15:08) CME information and select publications

On September 20th, 1917, at the Battle of Menin Road, Private Roy Inwood lay in the mud east of Ypres. His brother had died at Pozières the year before. In three hours, Roy would earn the Victoria Cross. The day after, he'd be dead.Nearby, three brothers from Petersham waited with their unit. By nightfall, their mother would have lost all three sons.After weeks of catastrophic failures under General Gough, Field Marshal Haig transferred command to General Herbert Plumer. In this episode, Mat McLachlan reveals how Plumer's methodical genius transformed the offensive: three weeks of preparation, limited objectives, overwhelming firepower—one gun for every five yards of front—and revolutionary tactics that reversed traditional doctrine.From predawn assembly through torrential mist to the devastating creeping barrage, we follow the 1st and 2nd Australian Divisions executing what Charles Bean called "probably their zenith"—the most perfectly coordinated attack of the war.Why did German counter-attacks fail so catastrophically? How did Plumer's "bite and hold" change tactical doctrine? What drove Roy Inwood to advance alone through his own barrage—twice?"Nothing I have heard in this world or can in the next could possibly approach its equal." - Australian soldier describing the barrageEpisode Length: 42 minutesFeatures: Frank Hurley's battlefield diary, German assessments of defensive collapse, and the Seabrook brothers' final day.Next Episode: Polygon Wood—the high point of the offensive.Presenter: Mat McLachlanProducer: Jess StebnickiReady to walk the battlefields? Join Mat's exclusive European tours: https://battlefields.com.au/Find everything Mat is doing at https://linktr.ee/matmclachlanFor more history: https://www.LivingHistoryTV.com Hosted on Acast. See acast.com/privacy for more information.

In this week's episode we'll learn about targeting NPM1 in acute myeloid leukemia. Researchers report the first clinical evidence of a menin inhibitor inducing complete remissions in AML with a NPM1 mutation. This validates NPM1 as a new therapeutic target in AML, alongside FLT3, IDH1/2, and KMT2A. Also on the podcast: targeting CD137 to prevent graft-versus-host disease. In nonhuman primates, a single dose of a CD137 antibody-drug conjugate provided long-term protection, with one important caveat: the potential for viral reactivation.Featured Articles: Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyA single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFS865. CME credit will be available until August 21, 2026.All Rise for Innovation in AML: Processing New Developments With Menin Inhibitors in Challenging AML Subtypes In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Johnson & Johnson, Kura Oncology, Inc., and Syndax.Disclosure information is available at the beginning of the video presentation.

It's the Top 10 Men! Who are the best men there ever have been? Find out here! Do you think you might be on the list? Are you one of the greatest men ever to have lived? Give it a listen and see if you are featured! Don't be sad if you're not, though.Rathergood Chat ep77 - Top Ten People Part 1: MENIn this episode, as well as the top 10 men, we also discuss electromagnet tennis, black holes, Mr Weebl, taxidermy and Victorian facial hair.Here are some timecodes for the people we talk about, in case you want to skip forward to a specific chap:02:35: Albert Einstein21:36: Spike Milligan26:16: Alexander Von Humboldt30:30: Genghis Khan38:11: David Attenborough43:36: Charles Darwin45:39: Leonardo Da Vinci48:01: Charles Dickens50:11: Dick Van Dyke53:33: Isaac Asimov57:17: Ranking Hosted on Acast. See acast.com/privacy for more information.

O 30º Congresso da The European Hematologya Association (EHA) aconteceu do dia 12 a 15 de junho de 2025 em Milão, Itália, e o Portal Afya fez a cobertura completa do evento e trouxe os principais destaques da programação científica.Neste episódio, a hematologista Luiza Lapolla aborda os principais temas discutidos no evento como: os inibidores de Menin no LMA, Ziftomenib na quimioterapia intensiva para pacientes com LMA recém-diagnosticados e estudos com temas específicos como o LD-venEx, POLAGRGO Trial e mais. Ouça agora!

Bugün İrem ile birlikte, yolda olmanın psikolojisi, birlikte yürümenin yola katkıları, doğayla yeniden ilişki kurmanın etkileri, hac yolculukları ve kendimizi yürümek üzerinden tanımaya dair keyifli bir sohbet gerçekleştirdik. Güzel dinlemeler!

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-clinical-trials-in-aml-with-menin-inhibitors/36185/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/menin-inhibitors-biologic-and-clinical-rationale/36179/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-menin-directed-aml-therapy/36184/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-menin-inhibitors/36182/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

#813 - Quem cede à pressão perde a missão | Pr.Diego Menin by Igreja do Amor

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.Presenters:Eytan M. Stein, MDChief, Leukemia ServiceDirector, Program for Drug Development in LeukemiaAssociate Attending PhysicianLeukemia Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkEunice S. Wang, MDChief, Leukemia ServiceProfessor of OncologyDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkLink to full program: https://bit.ly/4f4an0O

Evrim serimize devam ediyor ve 'Evrim sadece bir genetik kader mi yoksa çevreyle kurulan sürekli bir diyalog mu?' sorusunu cevaplamaya çalışıyoruz. 

Invités :  - Gabrielle Cluzel, écrivaine - Éric Naulleau, essayiste et journaliste - Docteur Jean-Paul Hamon - Gilbert Collard, ancien député européen - Laurent Menin, vice-Président de L'union Nationale des Entreprises de Coiffeurs Vous voulez réagir ? Appelez-le 01.80.20.39.21 (numéro non surtaxé) ou rendez-vous sur les réseaux sociaux d'Europe 1 pour livrer votre opinion et débattre sur grandes thématiques développées dans l'émission du jour.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this episode, we took a deep dive intro the landscape of menin inhibitors in AML with Dr. Eytan Stein from MSKCC. Here are the key trials and studies we discussed: ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutatedKOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstractSAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-ofKOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9 

261. bölümde QNB Dijital Köprü'nün KOBİ'lere yönelik dijital dönüşüm çözümlerini mercek altına alıyoruz. Konuklarım, QNB Dijital Köprü Pazarlama, Ürün ve Marka Yönetimi Bölüm Müdürü Yasemin Akemlek ve Stratejik İş Birlikleri, Müşteri Kazanımı ve Kanal Yönetimi Bölüm Müdürü Gözde Engüzel. (00:00) – Açılış (01:33) – Yasemin Akemlek ve Gözde Engüzel'i tanıyoruz. (03:57) - 20'den fazla dijital çözümün olduğu Dijital Köprü Platformuyla ilgili bu yayında e-Ticaret , e-İhracat ve imalar sektörlerine değineceğiz. KOBİ'lere yönelik son yenilikler neler ve en çok KOBİ'ler hangi hizmetleri istiyor? (05:25) – Üretim tarafında Dijital Köprü neler yapıyor? - Skala Üretim ve Envanter Yönetimi çözümü (09:10) – Üreticilerin bu hizmeti (Skala) kullanırken izledikleri yol nasıl oluyor? Bir üretici bu hizmeti kullanmak istese nerden başlıyorsunuz, nasıl yönlendiriyorsunuz? (11:18) – KOBİ'ler geleneksel yöntemlerle çalışıyorlar, ikna etmek için nasıl ilerliyorsunuz? (12:26) – e- İhracat tarafında platform nasıl bir fayda yaratıyor? (19:30) – Pazaryerlerine ürün yükleme nasıl oluyor? - StockMount e-Ticaret Pazaryeri çözümü (21:30) – Web sitesi alt yapı hazırlamak için nasıl bir yol izleniyor - İkas e-ticaret altyapısı çözümü (22:55) – Pazar yerlerine ek olarak kendi web sitenizden satış yapmak güvenilirlik açısından ne kadar önemli? (25:14) – Yurt dışına nasıl satış yaparım? e- İhracat büyüme rakamları nasıl? Dijital Köprü bu alanda nasıl destek oluyor? Envoyo e-İhracata İlk Adım çözümü (29:37) – Finansal raporların hazırlanması konusunda Dijital Köprü nasıl destek veriyor? Fincheckup Finansal Durum Raporu çözümü Promete finansal danışmanlık çözümü (34:58) – Başarı örnekleri ve geri bildirimler… (36:07) – Son sözler (37:30) – Kitap önerileri Can Dündar – Abim Deniz Dale Carnegie - Dost Kazanma ve İnsanları Kazanma Sanatı (38:50) - Kapanış Sosyal Medya takibi yaptın mı?   Twitter -⁠⁠⁠⁠⁠⁠⁠ https://twitter.com/dunyatrendleri⁠⁠⁠⁠⁠⁠⁠ Instagram -⁠⁠⁠⁠⁠⁠⁠ https://www.instagram.com/dunya.trendleri/⁠⁠⁠⁠⁠⁠⁠ Linkedin -⁠⁠⁠⁠⁠⁠⁠ https://www.linkedin.com/company/dunyatrendleri/⁠⁠⁠⁠⁠⁠⁠ Youtube -⁠⁠⁠⁠⁠⁠⁠ https://www.youtube.com/c/aykutbalcitv⁠⁠⁠⁠⁠⁠⁠ Goodreads - ⁠⁠⁠⁠⁠⁠⁠https://www.goodreads.com/user/show/28342227-aykut-balc⁠⁠⁠⁠⁠⁠⁠   aykut@dunyatrendleri.com Bize bağış yapıp destek olmak için Patreon hesabımız – ⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/dunyatrendleri⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Annalisa Menin"L'Anna che verrà"Giunti Editorewww.giunti.itÈ una torrida sera d'estate quando Anna chiama la sua migliore amica in preda a un attacco di panico. Non è l'ennesima disavventura sentimentale, ma qualcosa di molto più profondo, che ha scosso le fondamenta del suo essere. Adesso, alla soglia dei quarant'anni, Anna è di nuovo sola e terribilmente infelice. Non si riconosce più. Bisognosa di un cambio di prospettiva, decide di prendersi una pausa da tutto e di mollare il caos di New York. Torna nella tranquilla provincia veneta, in un luogo dove il tempo sembra essersi fermato: Casa Bohemia, una romantica stazione ferroviaria in stile anni '30. Tra un corso di giardinaggio e una sessione di filosofia, Anna ricomincia così a mettere insieme i pezzi della sua vita, facendo i conti con il suo passato ma anche con un'idea di futuro che non corrisponde più a ciò che aveva sognato da ragazza. E proprio come un giardino all'inglese, libero eppure controllato, ritroverà nell'imperfetta perfezione della natura un nuovo inizio. Perché non è mai troppo tardi per diventare chi si vuole essere e la relazione con noi stessi è quella più importante della nostra esistenza.Annalisa MeninÈ una scrittrice e imprenditrice esperta di Branding e Comunicazione. Veneziana di nascita, naturalizzata americana, si divide tra New York e l'Europa dal 2006. L'Anna che verrà è il volume conclusivo di un'idea­ le trilogia iniziata con il volume autopub­blicato Il mio ultimo anno a New York (2017) e proseguita con Il Traghettatore (Giunti 2021). Grazie all'iniziativa benefica “Remembe­ring Marco”, supporta giovani studenti italiani in procinto di vivere il Sogno Americano.IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Aplink Tauragę spiečiasi darbštūs, kūrybingi ir racionalūs svajokliai.Kęstutis Plyskaitis kaldintomis skulptūromis gražina Tauragę ir kraštą. Skalsaus pokalbio užsukime į kalvio dirbtuvę. Apie ką? Meninė kalvystė. Mokymai – šaudymas pistoletu. Savanoriška parama Ukrainos frontui.Vakar vadovas mažmeninėje prekybos įmonėje, šiandien – kvapų kūrėjas ir ne tik... Alius Verumbickas išleido poezijos rinkinį.Norvegiška patirtis perkelta į Eičius? Vidury girios šaknis įleido Eičių bendruomenės Karšuva pirmininkas Simas Gaidelionis su žmona Ieva. Žygeiviams Eičių kaimas tikras atradimas! Jame prasideda Simo kuriamos trasos po Karšuvos girią. Kas mėgsta iššūkius, miške gali apsigyventi kupole. Ieva tikra svajoklė! Susapnavo, kad Eičių vandens bokšte įkurs viešbutį.Ved. Jolanta Jurkūnienė

Continuing our journeys along the roads which crisscross the landscape of the Western Front, we travel to Flanders in Belgium, and take the old Roman road between the city of Ypres and the town of Menin which follows the story of four years of conflict here in the First World War and discuss once more the 'culture' of The Old Front Line.Got a question about this episode or any others? Drop your question into the Old Front Line Discord Server or email the podcast.Send us a textSupport the show

Newly diagnosed acute myeloid leukemia (AML) is traditionally treated with intensive chemotherapy for eligible patients, but ongoing research is exploring... The post Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more! appeared first on VJHemOnc.

Cloud e sanità: problema o opportunità? Cosa significa, in un contesto regolamentato, portare "fuori" i dati? A fronte di quali vantaggi? Quali sono le opportunità di Digital Transformation? Ne parliamo con Saverio Menin, Chief Software Architect di Santagostino.KudosEmanuele Garofalo per la postproduzione dell'episodioContattiTutti i podcast di Improove: https://www.improove.tech/podcastCanale Telegram di Improove: https://t.me/improove_techCanale Telegram di Cloud Champions: https://t.me/CloudChampions

Director Andrew Kightlinger IG@Andrew.vhs and DP Idan Menin IG:@idanmenin talk about their film, from Sylvester Stallone's Balboa Productions, "Lost On a Mountain in Maine" https://www.lostonamountaininmainemovie.com/Matt and Oren go deep about the tough trade-offs they made between budget, VFX, and the need to look realistic. And the guys delve into a wider discussion about the dance between great cinematography and awesome storytelling. Can you shoot on an iPhone and use it alongside an Alexa 35? Would you do it In a commercial, but not in a film and why? And how do you build a relationship between you, as director and your DP that elevates everyone's reel?As always, Oren and Matt get behind the real story to working on a film produced by Sylvester Stallone. Don't miss these juicy details!!---Get a great deal on Magic Mind! https://magicmind.com/shootitjanMatt's Endorsement: Go to a nice movie theater! Oren's Endorsement: Every Frame A Picture's video on YouTube, "Where Do You Put the Camera?" https://youtu.be/wa1O3nqW5hQ?si=ttIU6t8vY0JGhIOeAndrew's Endorsement: "Paradise" on Hulu https://press.hulu.com/shows/paradise/Idan's Endorsement: The liquid emulsion process for creating photographs on a silver-based, liquid photographic emulsion adhered to unconventional surfaces like wood blocks or concrete. Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

In this podcast, we bring you exclusive updates in acute myeloid leukemia (AML) from the 66th American Society of Hematology... The post Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML appeared first on VJHemOnc.

Scott Menin | The Resolute One by Hope Community Church, Willow Grove

Welcome back to the Oncology Brothers podcast! In this episode, we dive into the highlights from ASH 2024, focusing on key studies in leukemia. Join hosts Drs. Rahul and Rohit Gosain as they discuss groundbreaking research with Dr. Uma Borate from The Ohio State University. Episode Highlights: •⁠  ⁠KOMET 007 Study: An in-depth look at the Phase 1 study on the Menin inhibitor Ziftomenib, exploring its promising results in frontline settings for patients with NPM1 mutations and KMT2A rearrangements. •⁠  ⁠CPX351 vs. 7+3 Induction: A discussion on the liposomal formulation CPX351 and its effectiveness compared to the traditional 7+3 induction therapy, particularly in patients with myelodysplasia-related AML. •⁠  ⁠Venetoclax Combinations: Insights into the use of Venetoclax in combination with various therapies, including its role in treating patients without actionable mutations. Key Takeaways: •⁠  ⁠The importance of NGS testing in identifying targetable mutations in AML. •⁠  ⁠Promising response rates and manageable toxicities associated with Menin inhibitors. •⁠  ⁠The ongoing debate regarding the best induction therapy for AML patients. Don't miss this informative discussion that sheds light on the evolving landscape of leukemia treatment! Subscribe for more updates on oncology topics, including lymphoma, CLL, and myeloma discussions from ASH 2024. Thanks for tuning in! We are the Oncology Brothers. Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

#753 - Profetizando obediência para 2025 - Diego Menin by Igreja do Amor

In this episode of the Epigenetics Podcast, we talked with Yadira Soto-Feliciano from MIT about her work on the Menin-MLL complex and the effect of small molecules on its stability in leukemia. We explore the pivotal moments that led her to cancer biology during her graduate studies, where her work included ground-breaking research on the role of the plant homeodomain Finger protein-6 (PHF-6) in leukemia. This work bridged the realms of chromatin accessibility, transcription factors, and cancer cell lineage, providing critical evidence for the concept of lineage plasticity in cancer biology—a topic that has gained significant traction in recent years. Dr. Soto-Feliciano discusses how advances in techniques like CRISPR and ChIP-sequencing have shaped her research, enabling deeper insights into the mechanisms underlying cancer cell identity. As our discussion transitions, Dr. Soto-Feliciano shares her experience in David Allis's lab, illustrating how the collaboration across diverse scientific disciplines enhanced her understanding of chromatin biology and generated significant insights into the mechanics of epigenetic regulation. Highlighting a recent 2023 publication, we unpack her findings related to the conserved molecular switch between MLL1 and MLL3 complexes. These discoveries revealed how the application of small-molecule inhibitors of the menin-MLL interaction can alter gene expression and affect leukemia cells' responses to treatments. We also touch on the operational dynamics within her lab at MIT, established during challenging times marked by the pandemic. Yadira is dedicated to fostering a collaborative and respectful environment among her team, comprised of PhD candidates and research technicians, all sharing a commitment to unraveling the complexities of chromatin regulation. She emphasizes the significance of understanding chromatin scaffold proteins and their role in regulating gene expression and genome organization.   References Soto-Feliciano, Y. M., Bartlebaugh, J. M. E., Liu, Y., Sánchez-Rivera, F. J., Bhutkar, A., Weintraub, A. S., Buenrostro, J. D., Cheng, C. S., Regev, A., Jacks, T. E., Young, R. A., & Hemann, M. T. (2017). PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes & development, 31(10), 973–989. https://doi.org/10.1101/gad.295857.117 Soto-Feliciano, Y. M., Sánchez-Rivera, F. J., Perner, F., Barrows, D. W., Kastenhuber, E. R., Ho, Y. J., Carroll, T., Xiong, Y., Anand, D., Soshnev, A. A., Gates, L., Beytagh, M. C., Cheon, D., Gu, S., Liu, X. S., Krivtsov, A. V., Meneses, M., de Stanchina, E., Stone, R. M., Armstrong, S. A., … Allis, C. D. (2023). A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. Cancer discovery, 13(1), 146–169. https://doi.org/10.1158/2159-8290.CD-22-0416 Zhu, C., Soto-Feliciano, Y. M., Morris, J. P., Huang, C. H., Koche, R. P., Ho, Y. J., Banito, A., Chen, C. W., Shroff, A., Tian, S., Livshits, G., Chen, C. C., Fennell, M., Armstrong, S. A., Allis, C. D., Tschaharganeh, D. F., & Lowe, S. W. (2023). MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. eLife, 12, e80854. https://doi.org/10.7554/eLife.80854   Related Episodes MLL Proteins in Mixed-Lineage Leukemia (Yali Dou) Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard)   Contact Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

Welcome to the show this week.  Our guest is cinematographer Idan Menin who is on to talk about his latest work on the film Lost on a Mountain in Maine. The film looks great and Idan has a ton of stories to share from pre-production all the way through to his work on set.  I really […] The post The Wandering DP Podcast: Episode #461 – Idan Menin appeared first on Cinematography Podcast & Tutorials.

Modern Wisdom Key Takeaways  Now more than ever,young men are uncertain about what the world needs from themThe increase in young male suicide may be due to men retreating from the difficulties and challenges of modern society “The state of feeling unneeded is literally fatal.” – Richard Reeves Four out of five teens who commit suicide are boys: Across every age group, the suicide rate is 4x higher amongst men than women There has been an expansion in the domains of neediness for women and a contraction in the domain of neediness for men The mental health field is more female-friendly than male-friendly; the whole field of mental health has been coded as female and feminine – and we wonder why men are not interested in it!  Young men feel politically homeless, and they especially do not feel welcomed by the political left; instead of turning to the left or the right, younger men tend to retreat Recently, there has been a massive increase in drug poisoning deaths among young men From 2001 to today in the United States, the increase in deaths from drug poisoning is equivalent to an additional 400,000 menIn the US, only half of men in their 30s and 40s without a college degree are in a household with childrenFor men, the old form of neediness as a protector has been significantly evacuated and replaced by nothing The best protector against despair is realizing that the world needs you Read the full notes @ podcastnotes.orgRichard Reeves is a writer, researcher and the Founder of the American Institute for Boys & Men. Men have been struggling for a long time. What exactly is going on? What resources can genuinely help modern men, and how can we better understand the dynamics that are driving this decline in male wellbeing. Expect to learn why Obama endorsed Richard's book, the scary trends about male suicide, why it's important for humans to feel needed, whether the Harris-Walz campaign has even considered men's existence, if this upcoming election will be decided by masculinity, Richard's thoughts on therapy for men and much more…. Sponsors: See discounts for all the products I use and recommend: https://chriswillx.com/deals Get 50% off your first Factor Meals box at https://factormeals.com/MW50 (automatically applied at checkout) Get expert bloodwork analysis and bypass Function's 300,000-person waitlist at https://functionhealth.com/modernwisdom (automatically applied at checkout) Get a 20% discount on your first order from Maui Nui Venison by going to https://mauinuivenison.com/modernwisdom (use code MODERNWISDOM) Get a 20% discount on the best supplements from Momentous at https://livemomentous.com/modernwisdom (automatically applied at checkout) Extra Stuff: Get my free reading list of 100 books to read before you die: https://chriswillx.com/books Try my productivity energy drink Neutonic: https://neutonic.com/modernwisdom Episodes You Might Enjoy: #577 - David Goggins - This Is How To Master Your Life: https://tinyurl.com/43hv6y59 #712 - Dr Jordan Peterson - How To Destroy Your Negative Beliefs: https://tinyurl.com/2rtz7avf #700 - Dr Andrew Huberman - The Secret Tools To Hack Your Brain: https://tinyurl.com/3ccn5vkp - Get In Touch: Instagram: https://www.instagram.com/chriswillx Twitter: https://www.twitter.com/chriswillx YouTube: https://www.youtube.com/modernwisdompodcast Email: https://chriswillx.com/contact - Learn more about your ad choices. Visit megaphone.fm/adchoices

Politi-Cast'te bu hafta gazeteciler Sedat Bozkurt ve Berna Can Türkiye gündeminin öne çıkan başlıklarını ele aldı. Yenidoğan Çetesi ile ilgili yaşanan olaylar ve tepkiler, toplumsal çürümenin ve ülke yönetimindeki eksikliklerin nasıl derinleştiğini gözler önüne serdi. Berna Can ve Sedat Bozkurt, olayların perde arkası ve Türkiye'nin sosyal, ekonomik ve siyasi yapısı üzerine konuştu. Learn more about your ad choices. Visit megaphone.fm/adchoices

Neden öpüşüyoruz?Ne zamandır öpüşüyoruz?Sadece biz mi? Bonobolar ve şempanzeler de öpüşüyor. Peki ama niçin?Yeni bir araştırmayla öpüşmenin tarihi bin yıl geriye gitti.Tam 4500 yıldır kayıtlı ve belgeli şekilde sevgililerimizin dudaklarına romantik öpücükler konduruyoruz.Yahuda bile Hz. İsa'yı bir öpücükle çarmıha gönderdi.Öpüşmenin 100 bin yıllık tarihi bu bölümde...İyi dinlemeler...Yeni Haller sizlerin desteğiyle yayına devam eden bir podcast kanalı.Bölümlerin daha sık yayınlanması, Yeni Haller'in yayın hayatının uzun olması için siz de aşağıdaki linklerden destek olabilirsiniz.Patreon'a özel bölümleri dinlemek, bölümlere herkesten 24 saat önce erişmek ve Yeni Halller'e destek olmak için:www.patreon.com/yenihallerYeni Haller'in bir de Buy Me A Coffee hesabı var artık. Buradan destek olmak çoook daha kolay. Patreon'da sorun yaşayanlar için açtım efendim. Buyurun:https://www.buymeacoffee.com/yenihallerEray Özer'e ulaşmak için:https://www.instagram.com/eray_ozerhttps://twitter.com/ErayOzeryenihallerpodcast@gmail.com